NasdaqGM:ATRCMedical Equipment
AtriCure (ATRC) Is Up 10.1% After Unveiling 2030 Revenue Goal And Trial-Driven Expansion Plans
Earlier this week, AtriCure outlined a goal of reaching US$1.00 billion in revenue by 2030, backed by its atrial fibrillation, left atrial appendage management, and postsurgical pain-management franchises, alongside launches such as cryoSPHERE MAX and expansion into amputation procedures.
An important angle is how ongoing BoxX-NoAF and LeAAPS clinical trials could, if outcomes are favorable, widen the clinical use cases for AtriCure’s devices and reshape its addressable market.
We’ll now...